DeepMed Research

Anidulafungin

Generic Name: Anidulafungin

Brand Names: Ecalta, Eraxis

Drug Type: Small Molecule

Chemical Formula: C_₅₈H_₇₃N_₇O_₁₇

CAS Number: 166663-25-8

Unique Ingredient Identifier: 9HLM53094I

Background: Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin.

Indication: 用于治疗食管念珠菌感染，念珠菌性败血症，念珠菌引起的腹腔脓肿及念珠菌性腹膜炎。

Associated Conditions: Bloodstream Infections (BSI), Candidemia, Candidiasis, Esophageal Candidiasis, Fungal peritonitis caused by Candida, Intraabdominal Abscess caused by Candida, Invasive Aspergillosis, Oropharyngeal Candidiasis

Clinical Trials

Translational PKPD Modeling of Anti-infective Drugs Used in Pediatric Units.

Active, not recruiting

Conditions: Population Modeling of Anti-infective Drugs

Interventions: Drug: Patients requiring cefotaxime treatment
Drug: Patients requiring fluconazole treatment
Drug: Patients requiring meropenem treatment
Drug: Patients requiring isavuconazole treatment
Drug: Patients requiring anidulafungin treatment

First Posted Date: 2022-06-22

Last Posted Date: 2022-06-22

Lead Sponsor: Poznan University of Medical Sciences

Target Recruit Count: 150

Registration Number: NCT05426499

Locations: 🇵🇱
Szpital Kliniczny im. Karola Jonschera Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznań, Szpitalna 27/33, Poland
🇵🇱
Wielkopolskie Centrum Onkologii, Poznań, Garbary 15, Poland
🇵🇱
Poznan University of Medical Sciences, Department of Clinical Pharmacy and Biopharmacy, Poznań, Rokietnicka 7, Poland

and more 1 locations

Azole-echinocandin Combination Therapy for Invasive Aspergillosis

Phase 3

Terminated

Conditions: Invasive Aspergillosis

Interventions: Drug: Azole
Drug: Anidulafungin

First Posted Date: 2021-05-06

Last Posted Date: 2024-05-07

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 66

Registration Number: NCT04876716

Locations: 🇧🇪
UZ Ghent, Ghent, Belgium
🇧🇪
UZ Leuven, Leuven, Belgium
🇳🇱
Erasmus Medical Center (EMC), Rotterdam, Zuid Holland, Netherlands

and more 1 locations

Anidulafungin Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ADOPT)

Phase 4

Completed

Conditions: Obesity Morbid

Interventions: Drug: Anidulafungin 100mg single dose iv

First Posted Date: 2013-12-27

Last Posted Date: 2020-12-01

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 8

Registration Number: NCT02021123

Locations: 🇳🇱
Radboud University Medical Center, Nijmegen, Gelderland, Netherlands
🇳🇱
St. Antonius hospital, Nieuwegein, Netherlands

Negative Beta Glucan in ICU Patients

Phase 4

Completed

Conditions: Candidemia

Interventions: Drug: Anidulafungin

First Posted Date: 2012-11-27

Last Posted Date: 2019-07-08

Lead Sponsor: Universidade Federal do Rio de Janeiro

Target Recruit Count: 85

Registration Number: NCT01734525

Locations: 🇧🇷
Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil

Effect of Weight and/or Obesity on Anidulafungin Drug Concentrations

Phase 4

Completed

Conditions: Obesity
Mycoses

Interventions: Drug: Anidulafungin

First Posted Date: 2011-03-03

Last Posted Date: 2019-01-09

Lead Sponsor: Texas Tech University Health Sciences Center

Target Recruit Count: 20

Registration Number: NCT01307930

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients

Phase 4

Completed

Conditions: Liver Disease
Fungal Infection

Interventions: Drug: Anidulafungin
Drug: Liposomal amphotericin B

First Posted Date: 2011-02-24

Last Posted Date: 2014-05-30

Lead Sponsor: Fundacion SEIMC-GESIDA

Target Recruit Count: 61

Registration Number: NCT01303549

Locations: 🇪🇸
Hospital de Bellvitge, Barcelona, Spain
🇪🇸
Hospital Vall d'Hebrón, Barcelona, Spain
🇪🇸
Hospital Clinic i Provincial, Barcelona, Spain

and more 9 locations

Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease

Phase 2

Completed

Conditions: Leukemia, Myeloid, Acute
Leukemia
Myelodysplastic Syndrome

Interventions: Drug: anidulafungin 200 mg q48h
Drug: anidulafungin 300 mg q72h

First Posted Date: 2010-11-30

Last Posted Date: 2020-12-08

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 26

Registration Number: NCT01249820

Locations: 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom

Completed

Conditions: Candidiasis

Interventions: Drug: anidulafungin

First Posted Date: 2010-09-15

Last Posted Date: 2014-04-16

Lead Sponsor: Pfizer

Target Recruit Count: 50

Registration Number: NCT01202253

Locations: 🇬🇧
Pfizer Investigational Site, London, United Kingdom

Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects

Phase 3

Withdrawn

Conditions: Aspergillosis
Neuroaspergillosis
Invasive Pulmonary Aspergillosis

Interventions: Drug: Voriconazole
Drug: Anidulafungin

First Posted Date: 2010-08-25

Last Posted Date: 2012-05-11

Lead Sponsor: Pfizer

Registration Number: NCT01188759

Anidulafungin in Patients With Hematologic Malignancies

Phase 2

Terminated

Conditions: Hematologic Malignancies

Interventions: Drug: Anidulafungin

First Posted Date: 2010-01-22

Last Posted Date: 2012-03-02

Lead Sponsor: Elisabethinen Hospital

Target Recruit Count: 10

Registration Number: NCT01053884

Locations: 🇦🇹
Elisabethinen hospital, Linz, Upper Austria, Austria

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy